4basebio UK Societas Director/PDMR Shareholding

 
TIDM4BB 
 
26 February 2021 
 
                             4basebio UK Societas 
 
                                (the "Company") 
 
                              Director's Dealing 
 
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on 
exploiting its intellectual property in the field of gene therapies and DNA 
vaccines, announces that, on 25 February 2021, Heikki Lanckriet, chief 
executive officer, acquired 3,000 ordinary shares at an average price of 345 
pence per share on behalf of persons closely associated with him. 
 
As a result of the acquisition of ordinary shares, Heikki Lanckriet's 
beneficial holding, including shares held by persons closely associated with 
him, comprises 1,240,003 ordinary shares representing 10.07 per cent. of the 
Company's issued share capital. 
 
This announcement contains inside information for the purposes of Article 7 of 
EU Regulation 596/2014. 
 
For further enquiries, please contact: 
 
4basebio UK Societas                                     [phone] 
Heikki Lanckriet 
 
Nominated Adviser                                        [phone] 
Cairn Financial Advisers LLP 
Jo Tuner / Sandy Jamieson 
 
Broker                                                   [phone] 
finnCap Ltd 
Geoff Nash/Richard Chambers/Charlotte Sutcliffe 
 
Notification and public disclosure of transactions by persons discharging 
managerial responsibilities and persons closely associated with them 
 
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 
596/2014 
 
1     Details of the person discharging managerial responsibilities/person closely 
      associated 
 
a.    Name                 Heikki Lanckriet 
 
2     Reason for 
      notification 
 
a.    Position/Status      Chief Executive Officer 
 
b.    Initial notification Initial 
      / 
      Amendment 
 
3     Details of the issuer, emission allowance market participant, auction platform, 
      auctioneer or auction monitor 
 
a.    Name                 4basebio UK Societas 
 
b.    LEI                  2138005D5SAG8FIR6G91 
 
4     Details of the transaction(s): section to be repeated for (i) each type of 
      instrument; (ii) each type of transaction; (iii) each date; and (iv) each place 
      where transactions have been conducted 
 
a.    Description of the   Ordinary Shares 
      financial 
      instrument, type of 
      instrument           ISIN: GB00BLD8ZL39 
 
      Identification Code 
 
b.    Nature of the        Acquisition of ordinary shares 
      transaction 
 
c.    Price(s) and volume       Volume(s)        Price (p) 
      (s) 
                                 a. 1,000        345p 
                                 b. 1,000        345p 
                                 c. 1,000        345p 
 
d.    Aggregated 
      information          -3,000 
                           -345 pence per share 
      - Aggregated Volume 
      - Price 
 
e.    Date of the          25/2/2021 
      transaction 
 
f.    Place of the         London Stock Exchange, AIM 
      transaction 
 
 
 
 
END 
 
 

(END) Dow Jones Newswires

February 26, 2021 02:00 ET (07:00 GMT)